ClinicalTrials.gg
CompletedNCT01106989Updated Mar 16, 2012

Study Evaluating Heated Lidocaine/Tetracaine Patch in Patients With Pain Associated With Myofascial Trigger Points

A Phase 2 interventional study of Heated lidocaine/tetracaine patch in Myofascial Pain Syndromes, sponsored by ZARS Pharma Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-03-16.

Sponsored by ZARS Pharma Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 36 studies in Myofascial Pain Syndromes with a site in United States — 8 open to participants now, 9 under way, none of them phase 3. Myofascial Pain Syndromes · United States.

Enrollment
22nd of 31
20 · median 50
Started
2010
the only one that year
Phase 2
6 of 36
2 open now
Registered
5th of 36
by date

Among the 36 studies in Myofascial Pain Syndromes with a site in United States, this one is the 22nd largest by enrollment of the 31 interventional ones that give a count, is the only one that started in 2010, is one of 6 in phase 2, and was the 5th registered.

Myofascial Pain Syndromes

339 studies on the registry are indexed under Myofascial Pain Syndromes; 66 are open to participants now.

Browse Myofascial Pain Syndromes studies →

Open to participants now

8 of the 36 studies in Myofascial Pain Syndromes with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 34 Myofascial Pain Syndromes studies recruiting now, 5 (15%) set no upper age limit and 26 (76%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Myofascial Pain Syndromes with a site in United States, or all of them as a file.
02

Study summary

The purpose of this pilot study is to explore the potential usefulness of a heated lidocaine 70 mg and tetracaine 70 mg topical patch for the treatment of pain associated with myofascial trigger points.

Read the detailed description

The purpose of this pilot study is to explore the usefulness of a heated lidocaine 70 mg and tetracaine 70 mg topical patch for the treatment of pain associated with myofascial trigger points. The study will consist of a 2-week, open-label treatment period followed by a 2 week follow-up period conducted at a single study site. Eligible patients must have a clinical diagnosis of pain (minimum 1-month duration) associated with up to 3 identifiable myofascial trigger points. A number of efficacy variables will be employed to evaluate their utility for assessing painful responses in this population.

03

Conditions studied

  • Myofascial Pain Syndromes
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • be at least 18 years of age
  • have a clinical diagnosis of pain (minimum 1-month duration) associated with up to 3 myofascial trigger points
  • have trigger points confined to the upper back, shoulder, and neck

Exclusion criteria

Exclusion Criteria:

  • have used any topically applied pain medication on the target treatment area within 3 days preceding the Screening/Baseline Visit
  • have used any topically applied pain medication on the target treatment area within 3 days preceding the Screening/Baseline Visit
  • have used any injected pain medication with 28 days preceding the Screening/Baseline Visit
  • are receiving class 1 antiarrhythmic drugs (ie, tocainide, mexiletine, etc.)

Other protocol-defined inclusion/exclusion criteria may apply.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Heated lidocaine/tetracaine patch

    Active

    Drug: Heated lidocaine/tetracaine patch

Interventions

  • DrugHeated lidocaine/tetracaine patch

    Drug page: Lidocaine

    Patients will be instructed to apply one heated lidocaine 70 mg and tetracaine 70 mg topical patch directly to each trigger point identified at the Screening/Baseline Visit (up to 3 trigger points). Patches will be administered for 4 hours, 2 times per day (total of 8 hours for each trigger point per day).

    Also known as: Synera

06

What researchers measure

Primary outcomes

  1. Pain intensity

    Time frame: Two weeks

Secondary outcomes

  1. Pain interference with activities (eg, general, normal work, sleep)

    Time frame: Two weeks

07

Study locations

1 site
  • The Center for Clinical Research
    Winston-Salem, North Carolina 27103, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2010, a primary completion of Dec 2010 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 16, 2010
First posted
Apr 20, 2010
Start
Jun 2010
Primary completionActual
Dec 2010
CompletionActual
Jan 2011
Results delay requested
Mar 14, 2012
Last update
Mar 16, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01106989
Lead sponsor
ZARS Pharma Inc.
Responsible party
Sponsor
First posted
Apr 20, 2010
Start date
Jun 2010
Primary completion
Dec 2010
Completion
Jan 2011
Last update
Mar 16, 2012

Study contacts

Richard L Rauck, MD
principal investigator · The Center for Clinical Research

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Lidocaine

Start the discussion